KALVISTA PHARMACEUTICALS INC

KalVista insiders sell 400k+ options as Chiesi merger closes—$27 cash, no dilution, but regulatory hold ups and governance shifts could impact post‑merger value.

KalVista insider Yea Christopher buys 33,800 shares at $7.07, a deep discount to $26.77, signaling confidence in EKTERLY’s future and investor buzz.

KalVista insider trades reveal CMO’s confidence: a modest post‑vesting buy signals potential upside amid a 125 % YTD rally and strong pipeline momentum.

KalVista insider buy signals CEO confidence amid RSU sales, suggesting optimism on clinical milestones and a potential upside for biotech investors.

Venrock’s $95 million sale of 5 M KalVista shares highlights a potential valuation shift—why the move matters for investors and the company’s future.

Insider selling at KalVista shows routine trades, not a red flag—investors see solid fundamentals and growth potential in EKTERLY.

CEO buy of 15,625 KalVista shares signals cautious optimism for its protease‑inhibitor pipeline, offering a subtle positive cue for value‑oriented investors.

KalVista insider buys: CDO Yea Christopher’s RSU‑triggered purchase of 1,774 shares signals confidence amid EKTERLY data hype, offering a cautious buy hint for investors.

CEO’s insider RSU buy at KalVista signals long‑term confidence as EKTERLY data rises, hinting a potential biotech turnaround for value‑oriented investors.

KalVista CEO’s new share purchase signals confidence in the company’s EKTERLY pipeline and could hint at future upside for investors.